Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.

Study Purpose

From the medical records of a series of patients operated on for incident grade II and III glioma, the primary objective is to evaluate the correlation between the molecular profile of tumours and preoperative imaging data (by FDG and FDOPA PET-scan and multimodal MRI).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Subject 18 years of age or older, having been informed of the research.
  • - Subject operated on with an incident glioma of grade II or III, histologically confirmed (WHO 2016 classification) - Subject for which all preoperative imaging data is available (MRI, FDG and FDOPA PET-scan) - Subject for which molecular data of the lesion are available.

Exclusion Criteria:

  • - Subject having signified his opposition to the use of his medical data.
  • - Subject under safeguard of justice, guardianship or trusteeship.
- Subject with incomplete or missing part of the molecular and/or imaging data

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04461002
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

GCS Ramsay Santé pour l'Enseignement et la Recherche
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Philippe METELLUS, MD PD
Principal Investigator Affiliation Hôpital Privé Clairval
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Enrolling by invitation
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Glioma
Additional Details

A retrospective monocentre study of medical data (clinical, histological, molecular and imaging) contained in the medical records of patients operated on for Grade II or III incident glioma.

Arms & Interventions

Arms

: Cohort

Retrospective cohort

Interventions

Other: - Retrospective analysis

Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hôpital Privé Clairval, Marseille, France

Status

Address

Hôpital Privé Clairval

Marseille, , 13009

Stay Informed & Connected